Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Rollout of New Inspection Protocols May Begin Next Year

Executive Summary

Despite great enthusiasm within the agency for a New Inspection Protocols Pilot Project, FDA officials are saying they don't expect to adopt the protocols for broader use in pharmaceutical facility preapproval and surveillance inspections until perhaps sometime in 2017. The protocols could make inspections more comparable – and could bring recognition to facilities that go beyond compliance.

You may also be interested in...



FDA Launches Protocol For Inspections Of Sterile Drug Manufacturing Facilities

US FDA expects the New Inspection Protocol Project (NIPP) it launched Nov. 9 to increase the consistency of its sterile manufacturing inspections – and the ability of those inspections to catch quality problems before they could lead to drug shortages.

New FDA Protocols Will Soon Boost Inspection Consistency

By the end of next year, new FDA protocols could bring more consistency from one inspection to the next and from one investigator to another.

FDA Aims for State of Quality with New Inspection Protocol Project

How will FDA investigators advance from today’s highly variable ‘traffic ticket’ inspection approach to tomorrow’s super consistent, semi-quantitative ‘state of quality’ assessments? The answer: A new inspection protocol project that FDA officials have been describing at recent conferences.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel